GLUCOSAMINE

Adults 1250 mg per day corresponding to one effervescent tablet Glucosamine 625 mg twice daily or one effervescent tablet Glucosamine 1250 mg once daily. Before intake the effervescent tablets must be dissolved in at least 100 ml water (½ glass) and can be taken independently from meals.

Glucosamine is not indicated for the treatment of acute painful symptoms. Relief of symptoms (particularly pain relief) may not be experienced until after several weeks of treatment and in some cases even longer. If pain relief is not achieved after 2-3 months, continued treatment with glucosamine should be re-evaluated.

Elderly Dose adjustment is not necessary in treatment of elderly. Children and Adolescents Glucosamine is not recommended for use in children and adolescents below 18 years, due to lack of data on safety and efficacy. Impaired renal and/or hepatic function As no studies have been conducted in patients with impaired renal and/or hepatic function, dosage recommendations cannot be given

The most common adverse reactions associated with treatment with glucosamine are described below. The reported adverse reactions are usually mild and transitory. In the table below, all causality adverse events are listed by system organ class and frequency (very common ≥1/10; common ≥1/100 to <1/10; uncommon ≥1/1,000 to <1/100; rare ≥1/10,000 to <1/1,000; very rare <1/10,000; not known (cannot be estimated from the available data)).

MedDRA System Organ Class Common (>1/100 to <1/10) Uncommon (>1/1000 to <1/100) Not known (cannot be estimated from the available data) Nervous system disorders Headache Tiredness - Dizziness Respiratory, thoracic and mediastinal disorders - - Asthma / Asthma aggravated Gastrointestinal disorders Nausea Abdominal pain Indigestion Diarrhoea Constipation - Vomiting Skin and subcutaneous tissue disorders - Rash Itching Flushing Angioedema Urticaria Metabolism and nutrition disorders - - Diabetes mellitus inadequate control Hypercholesterolae mia General disorders and administration site conditions - - Oedema / Peripheral oedema Cases of hypercholesterolemia, asthma, aggravated and diabetes mellitus inadequate control have been reported, but causality has not been established.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Glucosamine should not be used in children and adolescents below the age of 18, due to lack of data on safety and efficacy. A doctor should be consulted to rule out the presence of joint diseases for which other treatments should be considered.

In patients with impaired glucose tolerance, monitoring of the blood glucose levels and, where relevant, insulin requirements is recommended before start of treatment and periodically during treatment. In patients with a known risk factor for cardiovascular disease, monitoring of the blood lipid levels recommended, since hypercholesterolemia has been observed in a few cases in patients treated with glucosamine.

A report on exacerbated asthma symptoms triggered after initiation of glucosamine therapy is available (symptoms resolved after withdrawal of glucosamine). Asthmatic patients starting on glucosamine should therefore be aware of potential worsening of asthmatic symptoms.

Glucosamine contains sorbitol. Patients with hereditary problems of fructose intolerance should not take this medicine. This medicinal product contains 320 mg sodium per tablet, equivalent to 16% of the WHO. Should be used with caution in patients with cardiac insufficiency.

1. • Patients who are allergic to shellfish as the active substance is extracted from shellfish.